CIK 0001404644
- Non-accelerated filer
- Smaller reporting company
Neurogene Inc.
Sign in to watch- Ticker
- NGNE
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 980542593
- Phone
- +1 877-237-5020
- Business address
- 535 W 24TH STREET, 5TH FLOOR, NEW YORK, NY, 10011
- Former names
- Neoleukin Therapeutics, Inc., AQUINOX PHARMACEUTICALS, INC, AQUINOX PHARMACEUTICALS (USA) INC
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Open-market buy 10% owner bought 140,786 shares at an average $10.80 ($1,520,909)
- 4 Open-market buy 10% owner bought 190,079 shares at an average $9.33 ($1,773,653)
- 4/A Open-market buy 10% owner bought 202,623 shares at an average $8.28 ($1,677,083)
- 4 Open-market buy 10% owner bought 202,623 shares at an average $8.28 ($1,677,083)
- 3 Insider Initial Statement of Ownership
- 4 Other disposition Director disposed of 1,543,989 shares (other)
- 4 Open-market buy 10% owner bought 2,480,032 shares at $15.50 ($38,440,496)
- 4 Open-market buy VP Global Regulatory & Quality bought 3,575 shares at $17.81 ($63,671)
- 4 Open-market sale VP Technical Operations sold 35,887 shares at $18.67 ($670,010)
- 4 Open-market sale CFO, Vice President Finance sold 29,079 shares at $18.67 ($542,905)
- 4 Open-market buy VP Global Regulatory & Quality bought 1,600 shares at $24.36 ($38,976)
- 4 Open-market sale 10% owner sold 259,927 shares at an average $26.47 ($6,880,295)
- 4 Open-market sale 10% owner sold 1,514,821 shares at an average $22.41 ($33,944,876)
- 3/A Insider 3/A
- 3 Insider Initial Statement of Ownership
Page 12 of 15 · 287 filings